LundbeckUS

We are dedicated to advancing brain health and transforming lives. All posts are intended for US audiences only.

[LundbeckUS @LundbeckUS]

Lundbeck presents new primary data from the Phase IIb PROCEED trial in migraine today at the @AHSheadache Annual Scientific Meeting. Read more about the data at #AHSAM and our commitment to advancing migraine care: https://t.co/5yAbjn6F0x **This post is intended for US audiences only.**

[LundbeckUS @LundbeckUS]

Attending #AHSAM? Drs. Gottschalk and @AmaalStarlingMD will discuss real-world patient-reported outcomes following previous anti-CGRP treatment failure in the Canary Ballroom, tomorrow at 12:30pm. Lunch will be served. #BrainHealth

[LundbeckUS @LundbeckUS]

New migraine data at @ahsheadache 2026 highlight real-world data and post-hoc analyses on the impact of disease-related symptoms. #AHSAM

Read the full press release to learn more on what this means for patients: https://t.co/9aaHUhebr1

[LundbeckUS @LundbeckUS]

Attending #AHSAM? Join Lundbeck’s lunch symposium highlighting research on real-world patient-reported outcomes after anti-CGRP treatment failure, led by Drs. Christopher Gottschalk and @AmaalStarlingMD on Friday, June 5, 12:30pm. #BrainHealth

[LundbeckUS @LundbeckUS]

Did you know that migraine is a leading cause of disability worldwide? Over 60% of migraine patient respondents in the Lundbeck-sponsored Harris Poll Migraine Report Card survey reported experiencing anxiety and/or depression, highlighting the profound impact of this complex neurological disease that often effects many facets of life. Unfortunately, migraine is frequently underrecognized, fueling stigma. Lundbeck is raising awareness to breaking down stigma and advocating for better outcomes for migraine patients. Learn more about what patient resources are available: https://t.co/kgyB9fyXv2

#RaiseTheBarForMigraine

[LundbeckUS @LundbeckUS]

It's time to raise the bar for migraine care. In a recent collaborative survey with @AMFMigraine, 92% of respondents reported that migraine disease impacts their quality of life, and they want healthcare providers to better understand what that means for them. Patients and providers must foster meaningful conversations about disease impact, severity, and individualized goals. Together, we can redefine expectations for migraine care and improve quality of life for patients. Explore what resources are available to help you discuss migraine with your doctor: https://t.co/kgyB9fyXv2

#RaiseTheBarForMigraine

[LundbeckUS @LundbeckUS]

Results from the Phase II AMULET study of an investigational drug in patients with multiple system atrophy were recently published in @TheLancet Neurology. Learn more: https://t.co/SS7WMA08Wm.

*This post is intended for US audiences only*

[LundbeckUS @LundbeckUS]

Lundbeck, in collaboration with @AMFMigraine, created a survey to better understand patient experiences during provider visits, resulting in new insights on the important role healthcare providers play in initiating conversations about treatment options, goals setting, and shared decision making. Together, we can elevate care standards and address patients’ needs to improve outcomes for the migraine community. Get tools to help prepare for your next doctor’s visit: https://t.co/kgyB9fyXv2

#RaiseTheBarForMigraine

[LundbeckUS @LundbeckUS]

New interim real-world data on #migraine and related cognitive symptoms are being presented at @AANmember #AANAM today.

Read the full press release to learn more on what this means for patients:

Read the full press release: https://t.co/nqyCirY0q8

[LundbeckUS @LundbeckUS]

The Lundbeck-sponsored Harris Poll Migraine Report Card highlighted that, according to survey respondents, despite progress in treatment options, preventive care remains underutilized among patients whose migraine attack frequency qualifies them for preventive care. Updated professional society position statements emphasize the importance of using migraine-specific treatments. It’s time to Raise the Bar - patients and providers must elevate expectations for preventive care and foster meaningful dialogue around disease impact, severity, and individualized goals.

Get the tools: https://t.co/kgyB9fyXv2

#RaiseTheBarForMigraine

[LundbeckUS @LundbeckUS]

Proud to share Thomas Gibbs, EVP & President, Lundbeck US, has been named a Notable Leader in Health Care by @CrainsChicago. Under his leadership, our team shows up every day Powered by Purpose.

#AdvancingBrainHealth #TransformingLives #PoweredByPurpose

[LundbeckUS @LundbeckUS]

Lundbeck presents new data this week at the American Academy of Neurology Annual Meeting (#AANAM), spanning #migraine, developmental and epileptic encephalopathy (#DEE), and multiple system atrophy (#MSA). Together, these data highlight Lundbeck’s continued commitment to making progress in brain diseases with high unmet need. Learn more: https://t.co/QPPPzmcT9B **This post is intended for US audiences only.**

[LundbeckUS @LundbeckUS]

We’re proud to be named a USA TODAY @TopWorkplaces for the fourth consecutive year! At Lundbeck US, we foster a workplace where employees feel a deep sense of belonging and are empowered to make an impact. Learn more: https://t.co/XOzmWrUnbe #TopWorkplaces

[LundbeckUS @LundbeckUS]

Congratulations to Kim Hembrook on being named an @HBAnet Rising Star! Her impact, collaboration, and dedication make her one to watch. #HBARisingStar #HBAimpact

[LundbeckUS @LundbeckUS]

Congratulations to Molly Poarch on being named an @HBAnet Luminary! Her leadership, mentorship, and commitment to excellence continue to inspire across Lundbeck. #HBALuminary #HBAimpact

[LundbeckUS @LundbeckUS]

What if we reimagined what the future of migraine care could be? Moving beyond monthly headache days to a more holistic approach focused on quality of life is part of the new research being conducted in the migraine space. Learn how Lundbeck is helping to redefine “what good looks like”: https://t.co/kgyB9fyXv2

#RaiseTheBarForMigraine

[National Organization for Rare Disorders (NORD) @RareDiseases]

VP of Medical Affairs at @LundbeckUS, Amy Nicole Nayar, is speaking at the 2026 #NORDSymposium this April 14–15 about new approaches to #ClinicalTrial design in rare #epilepsy and how these methods can support multiple #RareDisease communities. Join us: https://t.co/CeWGgwt15j

[LundbeckUS @LundbeckUS]

Ann had never heard of multiple system atrophy (MSA) prior to being diagnosed. MSA is rare, progressive, and incurable. It impacts the patient’s movement, balance, and autonomic bodily functions. Read more about Ann’s story: https://t.co/yb73kyC0Hk #MSAAwareness #multiplesystematrophy #MSA

[LundbeckUS @LundbeckUS]

We’re honored to be named a @SeattleTimes Top Workplace for the third year in a row, ranking #2 on the large employers list! Thankful for curious, adaptable and accountable colleagues who make Lundbeck a Top Workplace: https://t.co/38OfSLg6FQ

#TopWorkplaces #LifeatLundbeck #Seattle

[LundbeckUS @LundbeckUS]

Mike wrote off his stumbling, waning strength and fine motor issues to age, lack of sleep or a need for more exercise before he was diagnosed with multiple system atrophy (MSA).

MSA is a rare, progressive disease that is frequently misdiagnosed. #MSAAwareness #multiplesystematrophy #MSA #BrainHealth